Celcuity, a biotechnology company focused on developing innovative treatments for various types of cancer, has made ...

Celcuity Inc. (NASDAQ:CELC) Q4 2025 Earnings Call Transcript March 25, 2026 Celcuity Inc. beats earnings expectations. Reported EPS is $-0.97, expectations were $-1.06. Operator: Good afternoon, ...

Despite a significant net loss, Celcuity Inc (CELC) advances with promising clinical milestones and a strong financial position to support future growth.

Q4 2025 earnings call: gedatolisib NDA priority review, VIKTORIA-1 data and launch plans ahead of July 2026 PDUFA—read now.

The U.S. Food and Drug Administration (“FDA”) accepted Celcuity’s New Drug Application (“NDA”) and granted Priority Review with a Prescription ...

Celcuity LLC reports fourth-quarter earnings Wednesday after market close, as the clinical-stage biotechnology company approaches a critical July decision from the Food and Drug Administration on its ...

Celcuity recently reported in the Journal of Clinical Oncology that its Phase 3 VIKTORIA-1 trial in PIK3CA wild-type HR-positive, HER2-negative advanced breast cancer showed gedatolisib-based regimens ...

As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus ...